While 2013 Annual Report Includes Gianvi And Ocella Drug Injury Cases, The Only Mention Of Beyaz And Safyral Legal Cases Is Regarding Patent Disputes
SUMMARY: From the Bayer 2013 Annual Report which was issued recently:
• As of February 10, 2014, the number of claimants in the pending lawsuits and claims in the United States totaled about 4,600 (excluding claims already settled)….
• As of February 10, 2014, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 8,250 claimants in the U.S. for a total amount of about US$1.69 billion. Bayer has only been settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism)….
• Such injuries are alleged by about 1,950 of the pending unsettled claimants.
We will continue to monitor the YAZ / Yasmin litigation, including the status of filed and unfiled Beyaz and Safyral cases involving blood clot side effects like deep vein thrombosis (DVT) and pulmonary embolism (PE).[Read this article in full at original source]